Table 2. Clinical outcome in patients taking tenecteplase.

MNI: Major neurological improvement

mRS: Modified ranking scale

SICH: Symptomatic intracerebral hemorrhage

Study	Early MNI No. (%)	mRS at 90 days (0-1) no. (%)	SICH No. (%)	Mortality in 90 days No. (%)
Haley et al. [9]	7 of 31 (22.6% ) in 0.1-mg/kg tenecteplase group, 11 of 31 (35.5%) in 0.25-mg/kg tenecteplase group, 4 of 19 (21.1% ) in 0.4-mg/kg tenecteplase group, and 5 of 31 (16.1%) in alteplase group	14 of 31 (45.2%) in 0.1-mg/kg tenecteplase group, 15 of 31 (48.4%) in 0.25-mg/kg tenecteplase group, 7 of 19 (36.8%) in 0.4-mg/kg tenecteplase group, and 13 of 31 (41.9%) in alteplase group	Present in 3 of 19 (15.8%) in the 0.4-mg/kg group, 2 of 31 (6.5%) in the 0.25-mg/kg tenecteplase group, 0 of 31 in the 0.1-mg/kg tenecteplase group, and 1 of 31 (3.2%) in the alteplase group	2 of 31(6.5% ) in the 0.1-mg/kg group, 7 of 31 (22.6%) in the 0.25-mg/kg group, 3 of 19 (15.8%) in the 0.4-mg/kg group and 8 of 31(25.8%) in the alteplase group
Parsons MW et al. [10]	32 (64%) in tenecteplase group vs 9 (36%) in alteplase group, p = 0.02	27 (54% ) in tenecteplase group vs 10 (40%) in alteplase group, p= 0.25	2 (4%) in tenecteplase group vs 3 (12%) in alteplase group, p= 0.33	4 (8%)  in tenecteplase group vs 3 (12%) in alteplase group, p= 0.68
Huang et al. [11]	19/47 (40%) in tenecteplase vs 12/49 (24%) in alteplase, p=0.10	7/47 (15%) in tenecteplase vs 7/49 (15%) in alteplase, p= 0.89	ECASS II definition : 3/52 (6%) in tenecteplase vs 4/51 (8%) in alteplase, p=0.59   SITS-MOST definition : 1/52 (2%) in tenecteplase vs 2/51 (4%) in alteplase, p=0.50	8/47 (17%) in tenecteplase vs 6/49 (12%) in alteplase, p= 0.51
Logallo et al. [14]	229/549 (42%) in tenecteplase vs 214/551 (39%) in alteplase, p=0.97	354/549 (64%) in tenecteplase vs 345/551 (63%) in alteplase, p= 0.52	15/549 (3%) in tenecteplase vs 13/551 (2%) in alteplase, p= 0.70	29/549 (5%) in tenecteplase vs 26/551 (5%) in alteplase, p=0.68